Atrium Therapeutics Inc (RNA)
Atrium Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies aimed at the heart. The company’s research efforts center on cardiomyopathies and related genetic and cardiac diseases. Its development-stage candidates include ATR 1072, a siRNA therapy designed to target PRKAG2 for PRKAG2 syndrome, and ATR 1086, a siRNA therapy directed at PLN for PLN cardiomyopathy. Atrium Therapeutics was incorporated in 2025 and is headquartered in San Diego, California. The company’s common stock is listed on NASDAQ under the symbol RNA.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RNA
|
$14.38
|
18.4% Upside
|
Undervalued
|
$25
|
105.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-3.5x
|
0.9x
|
5.7x
|
201.2 M
|
-57.506 M
|
1.3%
|
91.9%
|
12.2
|
—
|
110.3%
|
